AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04466241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 Mg Oral Tablet
Description: 1 tablet daily from Day 1 to Day 10
Study NCT02666430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan's insulin glargine
Study NCT02666430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Study NCT02011594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg Q2W intravenously
Study NCT02011594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Administered orally.
Study NCT03681002 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: structured lifestyle program
Description: Intensive Lifestyle counseling during one year
Study NCT02933996 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS+GA group
Description: The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
Study NCT01818570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPC-5650
Description: A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
Study NCT01818570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
Study NCT01391182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EACA
Description: EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
Study NCT01391182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
Study NCT05271201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill exercise (mild)
Description: mild intensity treadmill training.
Study NCT05271201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill exercise (moderate)
Description: moderate-intensity treadmill training
Study NCT00084539 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT01577537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: Vaginal gel, daily for 7 days
Study NCT01577537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal gel, daily for 7 days
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered IV infusion.
Study NCT04014400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suprathel or Xeroform donor site application
Description: The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
Study NCT04014400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suprathel or Xeroform donor site application
Description: The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
Study NCT02727140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga with Asana (yoga postures)
Description: Yoga intervention consisting of asana, breathing and relaxation, meditation
Study NCT02727140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga without Asana (yoga postures)
Description: Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
Study NCT03237585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rural response system (RRS) intervention to reduce violence against women
Description: The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
Study NCT01617733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: 4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
Study NCT04605419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Areas with Barrett's esophagus high-grade dysplasia will get an injection of calcium chloride in submucosa through an endoscopic system before getting electroporation
Study NCT02462070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion
Study NCT02462070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Lotion
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally.
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM.
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Administered IV infusion.
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally.
Study NCT02057133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Endocrine therapy administered orally.
Study NCT03581058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
Study NCT03447561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipatory + consummatory food reward
Description: Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake).
Study NCT03447561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consummatory food reward
Description: Exposure to consummatory food reward (drinking sips of chocolate milkshake).
Study NCT04324970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tookie Vest
Description: Tookie Vest
Study NCT01514266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin+Bioprine
Description: The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
Study NCT01514266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02761369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A multi-channel deep TMS device with an H-coil (Brainsway Ltd)
Description: A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
Study NCT03019601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Education
Description: Structured group education on family planning facilitated by Peer Champions
Study NCT01620190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01620190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT01247051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precoating
Description: preoperative filling of heart lung machine with patients blood
Study NCT01247051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard priming
Description: preoperative filling of heart lung machine with colloids
Study NCT00002837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Study NCT00002837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00002837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Study NCT00002837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02761369 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: A multi-channel deep TMS device with an H-coil (Brainsway Ltd)
Description: A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
Study NCT02144259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA immediately postpartum
Description: DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
Study NCT00002837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Study NCT02463851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVAC GOLD multielectrode catheter
Description: Cardiac ablation for Atrial Fibrillation
Study NCT02144259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Implanon immediately postpartum
Description: Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
Study NCT02463851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Force single-tip ablation catheter
Study NCT02346539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Single Acute dose
Study NCT02346539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine polacrilex
Description: Single Acute dose
Study NCT01464359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
Study NCT01464359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: On Days 7, 6 and 5 pre-transplant, 25 mg/m\^2 intravenously over 1 hour.
Study NCT01464359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
Study NCT01464359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours.
Study NCT01464359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
Study NCT01464359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if \<12 kg) intravenously every 6 hours
Study NCT01464359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
Study NCT01464359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m\^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source.
Study NCT04003870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CASO
Description: Customized arch support orthoses (CASO)
Study NCT04003870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HL
Description: Orthotic Heel Lift (HL)
Study NCT03370484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Water with 80 mg sucralose
Study NCT03370484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk mineral supplement
Description: Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
Study NCT01626885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214
Description: Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
Study NCT00688662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with sphincterotomy
Description: cutting the biliary sphincter muscle (sphincterotomy)
Study NCT00688662 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ERCP without sphincterotomy
Description: ERCP with sphincter manometry, but no sphincterotomy
Study NCT00647049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 8000mg/m2 i.v., max. 2 cycles
Study NCT00647049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2, max. 8 times
Study NCT00647049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 3000mg/m2 die i.v., 2 days (max. 2 cycles)
Study NCT00647049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
Study NCT00647049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustin
Description: 400mg/m2 i.v. for 1 day
Study NCT06574542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Push enteroscopy (PE)
Description: All patients enrolled in this study underwent evaluation using push enteroscopy (PE)
Study NCT06574542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: After push enteroscopy (PE), all patients subsequently underwent a colonoscopy on the same day or the next day. However, if a culprit lesion was identified during PE and the patient was considered at risk for undergoing colonoscopy, the colonoscopy was not performed and was presumed to be negative.
Study NCT02127840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synacthen infusion during adrenal venous sampling
Description: Adrenal venous sampling during Synacthen infusion
Study NCT00526890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Description: Oral Twice daily
Study NCT00526890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Weekly IV
Study NCT00526890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Weekly IV
Study NCT00526890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study
Study NCT00526890 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergoing radiation Therapy
Study NCT03389984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cutaneous
Description: SKIN BIOPSY
Study NCT02785172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Vehicle
Study NCT02785172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Cream
Description: Vehicle
Study NCT02785172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion
Study NCT02785172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate Cream
Description: Cream
Study NCT00551122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00551122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lenograstim
Study NCT00551122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Study NCT00551122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00551122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00551122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00551122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01760278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant Follicle Stimulating Hormone (rFSH)
Description: There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study.
Study NCT01760278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant Follicle Stimulating Hormone (rFSH)
Description: There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study.
Study NCT04211467 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT04351295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir
Study NCT04351295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: chloroquine oral tablets
Study NCT03730324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: Study subjects will undergo urine and plasma biomarker testing and mpMRI prior to biopsy
Study NCT03730324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine and plasma biomarkes.
Description: Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
Study NCT02933996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS+GA group
Description: The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
Study NCT02933996 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TEAS+GA group
Description: No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.